BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Canaccord Genuity Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity Group in a note issued to investors on Tuesday,Benzinga reports. They presently have a $171.44 target price on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 64.56% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. cut their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Finally, Berenberg Bank initiated coverage on BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $144.03.

BioNTech Trading Down 1.1 %

NASDAQ BNTX opened at $104.18 on Tuesday. The business’s 50-day moving average price is $116.76 and its two-hundred day moving average price is $113.06. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.98 billion, a PE ratio of -49.30 and a beta of 0.30. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the business posted $1.90 EPS. The business’s revenue was down 19.5% compared to the same quarter last year. On average, analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently made changes to their positions in the stock. Daiwa Securities Group Inc. boosted its stake in BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after buying an additional 128 shares during the period. Bank of New York Mellon Corp boosted its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares during the period. Probity Advisors Inc. raised its holdings in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares in the last quarter. Midwest Professional Planners LTD. boosted its position in BioNTech by 5.8% during the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after acquiring an additional 222 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its stake in BioNTech by 3.9% in the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock worth $666,000 after purchasing an additional 224 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.